ALTO · Alto Ingredients, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $224.68M | - | $240.99M | $218.44M | $226.54M | - | $251.81M | $236.47M | $240.63M | - |
| Cost of Revenue | $215.46M | - | $217.49M | $220.37M | $228.35M | - | $245.85M | $228.91M | $243.03M | - |
| Gross Profit | $9.22M | - | $23.49M | ($1.94M) | ($1.81M) | - | $5.96M | $7.55M | ($2.40M) | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $6.70M | - | $6.51M | $6.17M | $7.19M | - | $7.51M | $8.96M | $7.93M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | $1.63M | - |
| D&A | $6.37M | - | $6.26M | $6.36M | $6.27M | - | $6.06M | $6.08M | $5.73M | - |
| Operating Income | $2.52M | - | $16.98M | ($8.11M) | ($9.00M) | - | ($720.0K) | ($1.41M) | ($10.33M) | - |
| Interest Expense | $2.20M | - | $2.80M | $1.67M | - | - | - | - | $886.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | $4.27M | - | $14.21M | ($11.00M) | ($11.68M) | - | ($2.44M) | ($3.11M) | ($11.72M) | - |
| EPS - Basic | $0.05 | - | $0.19 | ($0.15) | ($0.16) | - | ($0.04) | ($0.05) | ($0.17) | - |
| EPS - Diluted | $0.05 | - | $0.19 | ($0.15) | ($0.16) | - | ($0.04) | ($0.05) | ($0.17) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.31M | $23.41M | $32.52M | $29.77M | $26.78M | $35.47M | $33.59M | $27.12M | $29.31M | $30.01M |
| Accounts Receivable | $59.70M | $55.07M | $54.76M | $57.45M | $65.46M | $58.22M | $52.04M | $64.08M | $58.08M | $58.73M |
| Inventory | $52.83M | $61.68M | $53.39M | $53.87M | $50.61M | $49.91M | $48.01M | $49.43M | $42.61M | $52.61M |
| Accounts Payable | $19.30M | $14.51M | $15.52M | $15.71M | $17.03M | $20.37M | $17.20M | $20.13M | $18.51M | $20.75M |
| Current Assets | $158.55M | $155.92M | $150.92M | $149.72M | $153.46M | $153.12M | $145.15M | $153.66M | $150.84M | $168.77M |
| Total Assets | $386.29M | $388.79M | $388.47M | $393.06M | $402.21M | $401.44M | $417.41M | $432.50M | $434.63M | $454.24M |
| Current Liabilities | $41.65M | $59.07M | $42.42M | $42.51M | $53.12M | $57.80M | $45.10M | $49.77M | $55.05M | $65.29M |
| Long-term Debt | $73.06M | $63.03M | $100.60M | $118.32M | $110.66M | $92.90M | $83.34M | $90.96M | $84.07M | $82.10M |
| Total Liabilities | $136.41M | $143.54M | $166.07M | $185.22M | $188.29M | $176.38M | $153.49M | $166.68M | $165.98M | $174.68M |
| Stockholders' Equity | $249.88M | $245.24M | $222.40M | $207.84M | $213.92M | $225.06M | $263.93M | $265.82M | $268.66M | $279.56M |
| Retained Earnings | ($808.13M) | ($812.09M) | ($833.58M) | ($847.47M) | ($836.16M) | ($824.17M) | ($782.13M) | ($779.38M) | ($775.95M) | ($763.91M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.21M | - | - | - | ($18.23M) | - | - | - | $1.43M | - |
| Investing Cash Flow | ($909.0K) | - | - | - | ($7.81M) | - | - | - | ($6.04M) | - |
| Financing Cash Flow | ($7.33M) | - | - | - | $17.00M | - | - | - | $1.21M | - |
| CapEx | $909.0K | - | - | - | $532.0K | - | - | - | $4.64M | - |
| Free Cash Flow | $3.30M | - | - | - | ($18.76M) | - | - | - | ($3.21M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 4.1% | - | 9.7% | -0.9% | -0.8% | - | 2.4% | 3.2% | -1.0% | - |
| Operating margin | 1.1% | - | 7.0% | -3.7% | -4.0% | - | -0.3% | -0.6% | -4.3% | - |
| EBITDA margin | 4.0% | - | 9.6% | -0.8% | -1.2% | - | 2.1% | 2.0% | -1.9% | - |
| Net margin | 1.9% | - | 5.9% | -5.0% | -5.2% | - | -1.0% | -1.3% | -4.9% | - |
| Free cash flow margin | 1.5% | - | - | - | -8.3% | - | - | - | -1.3% | - |
| FCF / Net income | 0.77 | - | - | - | 1.61 | - | - | - | 0.27 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 3.0% | - | 2.7% | 2.8% | 3.2% | - | 3.0% | 3.8% | 3.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | 1.1% | - | 3.7% | -2.8% | -2.9% | - | -0.6% | -0.7% | -2.7% | - |
| Return on equity | 1.7% | - | 6.4% | -5.3% | -5.5% | - | -0.9% | -1.2% | -4.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.81 | 2.64 | 3.56 | 3.52 | 2.89 | 2.65 | 3.22 | 3.09 | 2.74 | 2.59 |
| Quick ratio | 2.54 | 1.60 | 2.30 | 2.25 | 1.94 | 1.79 | 2.15 | 2.09 | 1.97 | 1.78 |
| Cash ratio | 0.49 | 0.40 | 0.77 | 0.70 | 0.50 | 0.61 | 0.74 | 0.55 | 0.53 | 0.46 |
| Leverage | ||||||||||
| Debt / Equity | 0.29 | 0.26 | 0.45 | 0.57 | 0.52 | 0.41 | 0.32 | 0.34 | 0.31 | 0.29 |
| Debt / Assets | 0.19 | 0.16 | 0.26 | 0.30 | 0.28 | 0.23 | 0.20 | 0.21 | 0.19 | 0.18 |
| Debt / EBITDA | 8.22 | - | 4.33 | - | - | - | 15.61 | 19.49 | - | - |
| Interest coverage | 1.1x | - | 6.1x | -4.9x | - | - | - | - | -11.7x | - |
| Equity multiplier | 1.55 | 1.59 | 1.75 | 1.89 | 1.88 | 1.78 | 1.58 | 1.63 | 1.62 | 1.62 |
| Liabilities / Assets | 0.35 | 0.37 | 0.43 | 0.47 | 0.47 | 0.44 | 0.37 | 0.39 | 0.38 | 0.38 |
| Efficiency | ||||||||||
| Asset turnover | 0.58 | - | 0.62 | 0.56 | 0.56 | - | 0.60 | 0.55 | 0.55 | - |
| Inventory turnover | 4.08 | - | 4.07 | 4.09 | 4.51 | - | 5.12 | 4.63 | 5.70 | - |
| Days sales outstanding | 97d | - | 83d | 96d | 105d | - | 75d | 99d | 88d | - |
| Days inventory outstanding | 89d | - | 90d | 89d | 81d | - | 71d | 79d | 64d | - |
| Days payable outstanding | 33d | - | 26d | 26d | 27d | - | 26d | 32d | 28d | - |
| Cash conversion cycle | 154d | - | 146d | 159d | 159d | - | 121d | 146d | 124d | - |
| Valuation | ||||||||||
| P / E | 96.8x | - | 5.7x | - | - | - | - | - | - | - |
| P / B | 1.5x | - | 0.4x | 0.4x | 0.4x | - | 0.5x | 0.4x | 0.6x | - |
| P / S | 1.7x | - | 0.3x | 0.4x | 0.4x | - | 0.5x | 0.5x | 0.7x | - |
| EV / EBITDA | 47.7x | - | 6.4x | - | - | - | 31.6x | 36.5x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -0.8% | - | -4.3% | -7.6% | -5.9% | - | -20.8% | -25.5% | -23.3% | - |
| Revenue CAGR (3y) | -10.5% | - | -10.6% | -9.8% | -9.7% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | 294.2% | - | 24.7% | - | 43.2% | -56.0% | 24.1% | - |
| Operating income growth (YoY) | - | - | - | -475.9% | 12.9% | - | 83.4% | - | 11.1% | - |
| Net income growth (YoY) | - | - | - | -254.1% | 0.4% | - | 30.0% | - | 10.9% | - |
| EPS growth (YoY) | - | - | - | -200.0% | 5.9% | - | 20.0% | - | 5.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -483.8% | - | - | - | 90.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 16.8% | 9.0% | -15.7% | -21.8% | -20.4% | -19.5% | -11.4% | -11.6% | -8.5% | -9.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.61B totalPekin Campus Sales$591.49M · 36.6%
Pekin Campus Production$415.80M · 25.7%
Total Marketing And Distribution Sales$231.13M · 14.3%
Marketing And Distributions$221.31M · 13.7%
Total Western Production Sales$100.55M · 6.2%
Western Production Segment$67.30M · 4.2%
Intersegment Eliminations($12.61M) · -0.8%
Peer comparison
Same SIC group: Industrial Organic Chemicals
Comparing Alto Ingredients against the 5 most active filers in the same SIC group.